Biocept Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BIOC Nasdaq 2834 https://biocept.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biocept Inc

Biocept Reports First Quarter 2022 Financial Results - May 23rd, 2022 8:05 pm
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q - May 16th, 2022 8:05 pm
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 8th, 2022 8:05 pm
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results - Apr 6th, 2022 12:00 pm
Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance - Mar 31st, 2022 10:15 pm
Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022 - Mar 18th, 2022 12:00 pm
Biocept Appoints Philippe Marchand as Chief Operating Officer - Mar 8th, 2022 1:17 pm
Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer - Feb 22nd, 2022 9:17 pm
Biocept, Inc. (NASDAQ:BIOC) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Feb 18th, 2022 9:54 am
Biocept Appoints Samuel D. Riccitelli as Interim President and Chief Executive Officer and Antonino Morales as Interim Chief Financial Officer - Feb 16th, 2022 9:05 pm
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer - Feb 10th, 2022 1:17 pm
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant - Jan 21st, 2022 1:00 pm
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year? - Jan 7th, 2022 2:40 pm
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10 - Jan 4th, 2022 1:00 pm
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain - Dec 9th, 2021 1:17 pm
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test - Dec 3rd, 2021 11:49 am
Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression - Nov 22nd, 2021 6:56 pm
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season - Nov 22nd, 2021 1:17 pm
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer - Nov 18th, 2021 7:45 pm
Biocept Reports Third Quarter 2021 Financial Results - Nov 15th, 2021 9:05 pm